<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02835976</url>
  </required_header>
  <id_info>
    <org_study_id>WP29867</org_study_id>
    <secondary_id>2014-002470-37</secondary_id>
    <nct_id>NCT02835976</nct_id>
  </id_info>
  <brief_title>A Study of the Excretion Balance of Radiocarbon and the Pharmacokinetics and Metabolic Profile of TRO19622 (Olesoxime)</brief_title>
  <official_title>A Single-Center, Open-Label, Single Oral Dose Phase I Study to Determine the Excretion Balance of Radiocarbon (i.e., the Sum of 14C-Labeled TRO19622 and Its 14C-Metabolites) and to Investigate the Pharmacokinetics and Metabolic Profile of TRO19622</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Trophos SA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This Phase I study is designed to determine the excretion balance of radiocarbon, as the sum
      of carbon-14 (14C)-labeled TRO19622 and its 14C-metabolites, and to investigate the
      pharmacokinetics and metabolic profile of TRO19622 (olesoxime) in healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T1/2 of Radiocarbon</measure>
    <time_frame>Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, 360, 408 h) following single dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Plasma Clearance (CL/F) of Olesoxime and Any Major Metabolite(s) Identified</measure>
    <time_frame>Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408 h) following single dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of Radiocarbon</measure>
    <time_frame>Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, 360, 408 h) following single dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of Olesoxime and Any Major Metabolite(s) Identified</measure>
    <time_frame>Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408 h) following single dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F of Radiocarbon</measure>
    <time_frame>Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, 360, 408 h) following single dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Amount of Olesoxime Excreted in Urine</measure>
    <time_frame>Continuous urine collection from pre-dose (0 h) to post-dose (432 h, or until release criteria are met) following single dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Amount of Olesoxime Excreted in Expired Air</measure>
    <time_frame>Pre-dose (0 h) and post-dose (8, 10, 12, 16, 24, 48, 72, 96 h) following single dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Amount of Olesoxime Excreted in Feces</measure>
    <time_frame>Continuous fecal collection from pre-dose (0 h) to post-dose (432 h, or until release criteria are met) following single dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CLr) of Olesoxime</measure>
    <time_frame>Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408 h) following single dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of Radiocarbon</measure>
    <time_frame>Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, 360, 408 h) following single dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of Radiocarbon</measure>
    <time_frame>Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, 360, 408 h) following single dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Continuously from Screening until 7 days after last dose (up to 46 days overall)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Olesoxime and Any Major Metabolite(s) Identified</measure>
    <time_frame>Pre-dose (0 hours [h]) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408 h) following single dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Radiocarbon</measure>
    <time_frame>Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, 360, 408 h) following single dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Maximum Observed Concentration (Tmax) of Olesoxime and Any Major Metabolite(s) Identified</measure>
    <time_frame>Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408 h) following single dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Radiocarbon</measure>
    <time_frame>Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, 360, 408 h) following single dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve from Drug Administration to Last Quantifiable Concentration (AUClast) of Olesoxime and Any Major Metabolite(s) Identified</measure>
    <time_frame>Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408 h) following single dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve Extrapolated to Infinity (AUCinf) of Olesoxime and Any Major Metabolite(s) Identified</measure>
    <time_frame>Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408 h) following single dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Half-Life (t1/2) of Olesoxime and Any Major Metabolite(s) Identified</measure>
    <time_frame>Pre-dose (0 h) and post-dose (2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408 h) following single dose on Day 1</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Olesoxime</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of liquid suspension of 14C-labeled olesoxime containing an equivalent of 600 milligrams (mg) of the compound. The total amount of administered radiocarbon will be 93 microcuries (mcCi), or 3.447 megabecquerels (MBq).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olesoxime</intervention_name>
    <description>Olesoxime will be given orally on Day 1 as a 600-mg liquid suspension within 30 minutes after starting a standardized high-fat breakfast.</description>
    <arm_group_label>Olesoxime</arm_group_label>
    <other_name>TRO19622</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) 20.0 to 28.0 kilograms per meter-squared (kg/m^2) and body
             weight at least 60 kilograms (kg)

          -  Fitzpatrick skin type less than (&lt;) 4

          -  Good health according to medical history, physical examination, laboratory parameters,
             vital signs, and 12-lead electrocardiogram (ECG)

          -  Negative urine test for drugs of abuse

          -  Negative alcohol breath test

          -  Negative tests for hepatitis or human immunodeficiency virus (HIV)

          -  Use of effective contraception during and for 3 months beyond study participant, among
             sexually active non-vasectomized participants with females partners of childbearing
             potential

        Exclusion Criteria:

          -  Concomitant or recent medication use within 2 weeks prior to Day 1, except for
             paracetamol

          -  Use of enzyme-inducing drugs within 2 months prior to Day 1

          -  Any medical condition that may alter the pharmacokinetics of olesoxime or affect
             interpretation of study results

          -  Irregular bowel movements

          -  Drug addiction or alcoholism

          -  Use of nicotine products

          -  Participation in another clinical study within 12 weeks prior to Day 1

          -  Exposure to ionizing radiation within one year prior to Day 1
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2016</study_first_submitted>
  <study_first_submitted_qc>July 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2016</study_first_posted>
  <last_update_submitted>July 14, 2016</last_update_submitted>
  <last_update_submitted_qc>July 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

